AstraZeneca is to invest £127m in a new Chinese factory as the pharmaceutical maker increases its stake in the fast-growing market.
The site represents AstraZeneca’s largest investment in a single manufacturing facility globally. It will make both intravenous and oral solid medicines for the company’s China business and will help AstraZeneca meet growing demand for its products in the country. With its burgeoning middle class and increasing government investment in improving healthcare, China’s pharmaceutical market has…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
